Our commitments

In 2012, we developed forward-looking commitments across the four areas of our responsible business approach.

They aim to address unmet health needs and are aligned with our strategic priorities and our values.

Each year we report on our progress against these commitments and here we provide a summary for those that relate to Our behaviour.

Promoting values in sales and marketing practices

Continue to drive a values-based approach to sales and marketing practices, with the interests of consumers and patients at its core.

Progress: On track

Completed the roll-out of our new sales compensation model in January 2015 and started work to change how we engage with healthcare professionals so that by 2016 we will no longer pay them to speak about our medicines. We have also changed the way we support education for doctors.

Close accordion

Rigorous patient and consumer safety

Continue to ensure the interests and safety of patients and consumers are of paramount importance in the way we design and undertake our clinical trials, our product quality assurance and our monitoring and reporting of adverse events in ongoing product usage.

Progress: Progressing well

Developed a Third Party Oversight programme that will consolidate and streamline our approach to managing third-party risk; introduced Fingerprint, an end-to-end supply chain serialisation programme that will further strengthen our anti-counterfeiting measures.

Close accordion

Minimising animal testing

Rigorously challenge the need for animal studies and work to minimise the impact on animal welfare, by investing in the development of alternative studies and sharing animal-based data.

Progress: Progressing well

Launched a strategic initiative that has the potential to reduce our reliance on animal studies; continued looking for new ways to develop medicines using human cells and tissues together with the European Bioinformatics Institute and the Sanger Institute.

Close accordion

Promoting Human Rights

Address the UN Guiding Principles on Human Rights and Business across our own operations and our supplier relationships.

Progress: On track

Increased focus on the human rights impacts identified by an external assessment of our business, for example through our Third Party Oversight programme.

Close accordion

Transparency in clinical trial data

Be as transparent as possible with our clinical trial data, including publishing clinical study reports (without patient-level data) for all outcome trials of medicines conducted by GSK and, within an appropriate process, making available to researchers access to anonymised patient level data to further scientific enquiry.

Progress: Progressing well

Led the development of www.clinicalstudydatarequest.com where researchers can now request access to anonymised patient level data from over 1,000 clinical trials by GSK and other companies.

Close accordion

Ensuring ethical stakeholder interactions

Demonstrate that all GSK interactions with patient advocacy groups and political stakeholders are conducted appropriately, ethically and transparently.

Progress: Progressing well

Enhanced Global Standard Operating Procedures on public policy group and government official engagement; first full year of implementation of an Emerging Markets patient advocacy strategy to broaden and deepen interactions with patient groups, whilst embedding the highest levels of transparency and governance.

Close accordion